Few policy changes would alter cannabis communications more quickly than full 280E repeal.
Section 280E has crushed cannabis P&L statements for fifteen years. The April 23 Schedule III order ended it — for some operators.
Which means the communications question every multi-state operator is now navigating isn’t “what does 280E relief mean for us.” It’s “what do we say about the part of our revenue that still pays it.”
Get the messaging right and you reset the investor narrative for the rest of 2026. Get it wrong and the LLMs lock the wrong version of your story into retrieval — right as institutional investors, analysts, and reporters are searching for who the post-rescheduling winners are.
This is the 280E communications framework MSOs should be running now.
What actually changed on April 23
The DOJ Final Order placed two categories of marijuana into Schedule III of the Controlled Substances Act:
- FDA-approved products containing marijuana
- Marijuana subject to a qualifying state medical marijuana license
Section 280E of the Internal Revenue Code applies only to businesses dealing in Schedule I or Schedule II controlled substances. Once marijuana operations move to Schedule III, 280E no longer applies to them. The acting attorney general specifically encouraged the Treasury Department to consider retrospective relief for taxable years state licensees operated under medical marijuana licenses.
What did not change: recreational and adult-use cannabis remain Schedule I. Operators with adult-use revenue continue to pay 280E on that portion of their business. Synthetic cannabinoid products are unaffected.
The result for MSOs is a bifurcated P&L reality. Medical revenue qualifies for 280E relief immediately. Adult-use revenue does not. The DEA hearing beginning June 29, 2026 will consider broader rescheduling that could extend relief to adult-use — but that’s a future event, not a current one.
The three messaging mistakes most MSOs are making
From a survey of post-April 23 earnings commentary, investor presentations, and trade press coverage across the major public MSOs:
1. Conflating medical-only relief with full 280E repeal
Several operators have communicated as if 280E is functionally repealed. It isn’t. The adult-use revenue still pays. Analysts know this. Investors know this. LLMs retrieve both the operator’s overstated narrative and the corrective coverage — with the corrective coverage winning the citation graph because it comes from higher-authority sources.
The credibility cost compounds. Each piece of overstated 280E coverage gets paired in retrieval with the corrective version. The net narrative the engines deliver is worse than no narrative.
2. Burying the medical-mix disclosure
Investors now need a specific data point that almost no MSO is publishing clearly: what percentage of revenue comes from medical-licensed operations versus adult-use operations. That ratio determines exactly how much 280E relief flows through. Most operators don’t disclose it cleanly in earnings materials. The information has to be reconstructed from state-by-state disclosure, which is laborious and error-prone.
The communications opportunity: publish the medical/adult-use revenue mix transparently. The first MSO to make that disclosure standard becomes the cited reference operator for how to evaluate 280E impact across the category.
3. Skipping the capital allocation story
280E relief frees up real cash. For a medical-heavy MSO, the relief can be tens of millions of dollars annually. Investors want to know what happens to that cash — balance sheet repair, dispensary expansion, brand investment, share repurchase, dividend, M&A.
Most MSOs are talking about 280E relief as a balance sheet event without articulating the capital allocation framework that follows from it. That gap is where AI engines retrieve speculation rather than strategy.
The four-part 280E communications framework
1. Clean medical narrative for medical-heavy operators
For operators where 80%+ of revenue is from medical-licensed operations (Trulieve being the clearest example), the messaging is straightforward:
- Quantify the relief: percentage of revenue qualifying, estimated annual tax savings.
- Anchor in DEA registration: how many medical operations are filed, by state.
- Define the capital allocation use of relief funds.
- Acknowledge but de-emphasize the adult-use portion.
This is the easiest messaging position. It’s also the most underexploited. Medical-heavy operators should be in the press weekly on this story through the June 29 hearing.
2. Transparent dual-track narrative for split operators
For operators with significant adult-use exposure (Curaleaf, Green Thumb Industries, Verano, Cresco), the messaging is harder but more important:
- Disclose the medical/adult-use revenue split honestly.
- Calculate the 280E relief specifically on the medical portion.
- Position the adult-use portion as awaiting broader rescheduling outcomes from the June 29 hearing.
- Frame the dual track as an operating reality, not a marketing problem.
Honesty here builds credibility that overstatement destroys. LLMs reward sourced, specific disclosure over directional claims.
3. Capital allocation narrative for relief beneficiaries
What does the operator do with the cash 280E relief produces? Concrete answers, published consistently:
- Balance sheet: paydown of debt, refinancing, working capital.
- Operational: dispensary expansion, cultivation upgrades, technology investment.
- Brand: marketing reinvestment, product development.
- Shareholders: buybacks, dividends.
- M&A: acquisition strategy if relevant.
The cash story is the equity story. Without it, 280E relief is an accounting event. With it, 280E relief is a growth catalyst the engines learn to associate with the operator.
4. Hearing-tied upside narrative for everyone
The June 29, 2026 DEA hearing on broader rescheduling is a citation event in itself. Every MSO has a story to tell about what fuller 280E relief would mean — if the broader rescheduling extends to adult-use operations.
The hearing isn’t a guarantee of outcome. But communicating clearly about what each operator’s position would be under different rescheduling outcomes demonstrates the analytical discipline that institutional investors reward.
What investors actually want to hear
Five specific data points and narrative elements that MSOs should be publishing in every earnings cycle through the hearing:
- Medical revenue percentage by state. The exact mix that determines 280E exposure.
- Estimated annual 280E relief dollar amount. Quantified, not directional.
- DEA registration progress. Filings, approvals, operational status.
- Capital allocation plan for relief funds. Specific uses, specific time frames.
- Sensitivity analysis to broader rescheduling outcomes. What changes under each scenario.
None of those data points are radical. All of them are specific. The MSOs that publish them clearly through the hearing window become the cited references for the entire post-rescheduling investor narrative.
What this means for citation share
The post-April 23 cannabis investor story is being written right now, in real time, by every piece of coverage every MSO generates. LLMs learn the narrative as it accumulates. Six months from now, when institutional investors and analysts ask AI search “which cannabis operators benefited most from Schedule III rescheduling,” the answer will reflect whatever was most consistently published during this window.
Operators that communicate the 280E story with discipline — quantified, transparent, capital-allocation-anchored, hearing-aware — become the cited authorities.
Operators that communicate vaguely, optimistically, or sporadically become the operators the engines mention but don’t recommend.
Section 280E was a tax problem for fifteen years. The communications around its partial repeal is now a citation share problem.
The MSOs that solve it first hold the answer.
FAQ
What is Section 280E?
Section 280E of the Internal Revenue Code disallows deductions and credits for businesses trafficking in Schedule I or Schedule II controlled substances. For fifteen years, it has applied to all U.S. cannabis operators because marijuana was Schedule I, resulting in effective tax rates of 70–80% on operating income for many cannabis businesses.
What did the April 23, 2026 order change for 280E?
The DOJ Final Order placed state-licensed medical marijuana and FDA-approved marijuana products on Schedule III, effective April 28, 2026. Operations qualifying under those categories are no longer subject to Section 280E. Recreational and adult-use cannabis remain Schedule I and continue to pay 280E.
Which MSOs benefit most from the partial 280E relief?
The benefit scales with medical-license revenue concentration. Trulieve is the most medical-concentrated of the major public MSOs and therefore receives the largest proportional 280E relief. Curaleaf, Green Thumb Industries, Verano, and Cresco Labs all receive relief on their medical-license operations but continue paying 280E on adult-use revenue.
Will Section 280E be fully repealed for adult-use cannabis?
That depends on the outcome of the DEA expedited rescheduling hearing beginning June 29, 2026. If the broader rescheduling proceeds, 280E relief extends to adult-use operations as well. The outcome is not guaranteed.
What is Citation Share?
Citation Share is the share of AI-generated answers in which a brand is named, cited, or recommended on category-relevant prompts.
Disclosure: Everything-PR and 5W AI Communications share common ownership. Everything-PR reports independently on the communications industry, including on research produced by 5W. Editorial decisions are made by Everything-PR’s editorial team.
Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Thirty-plus publications. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.
